1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)

Jason M. Pogue, PharmD, BCPS, BCIDP; Ronald N Jones, MD; John S Bradley, MD; David Andes, MD; Sujata M. Bhavnani, PharmD, MS, FIDSA; Michael Dudley, PharmD; Robert P. Staum, PhD, Keith A. Rodvold, PharmD; Paul G. Ambrose, PharmD, FIDSA; University of Michigan College of Pharmacy, Ann Arbor, Michigan; United States Committee on Antimicrobial Susceptibility Testing (USCAST), Silverton, Oregon; Institute for Clinical Pharmacodynamics, Inc., Scenectady, New York; Nihonkai Hospital; United States Committee on Antimicrobial Susceptibility Testing (USCAST), San Diego, California

Session: 162. PK/PD and Susceptibility Testing
Friday, October 4, 2019: 12:15 PM

1535. Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of Ceftepime (CPM) in Obese and Non-Obese Patients

Taylor Morrisey, PharmD; Nichole Neville, PharmD; Scott W. Mueller, PharmD; Abbie Britton, PharmD; Gabrielle Jacknin, PharmD; Matthew A. Miller, PharmD; Douglas N. Fish, PharmD; University of Colorado School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado; Swedish Medical Center, Aurora, Colorado; University of Colorado Hospital, Aurora, Colorado

Session: 162. PK/PD and Susceptibility Testing
Friday, October 4, 2019: 12:15 PM

1536. Population Pharmacokinetic Analysis of Baloxavir Marboxil, a Capsaicin-Dependent Endonuclease Inhibitor, in Adult and Adolescent Healthy Subjects and Influenza Patients and Exposure-Response Relationships in the Patients at High-Risk of Influenza Complications

Hiroki Koshimichi, MS; Sylvie Retout, PharmD; Valère F Cosson, PharmD, PhD; Stefan De Buck, PhD; Yoshiyu Tsuda, BS; Toru Ishibashi, PhD; Toshihiro Wajima, PhD; Shinogi & Co., Ltd., Osaka, Japan; T. Hoffmann-La Roche Ltd., Boulogne Billancourt Cedex, Ile-de-France, France; T. Hoffmann-La Roche Ltd., Basel, Basel-Stadt, Switzerland; T. Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland

Session: 162. PK/PD and Susceptibility Testing
Friday, October 4, 2019: 12:15 PM

Disclosures. All authors: No reported disclosures.